{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonatal+Infection", "query": { "condition": "Neonatal Infection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 604, "total_pages": 61, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonatal+Infection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T09:18:39.397Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00104923", "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2005-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104923" }, { "nct_id": "NCT05406583", "title": "A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Dolutegravir 0.5 mg/kg oral suspension", "type": "DRUG" }, { "name": "Dolutegravir 5 mg Dispersible Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 48, "start_date": "2022-10-05", "completion_date": "2025-05-22", "has_results": false, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05406583" }, { "nct_id": "NCT01994603", "title": "Expansion to Interdisciplinary HIV Prevention in Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV", "AIDS", "Fetal Alcohol Syndrome", "Alcohol Related Neurodevelopmental Disorder" ], "interventions": [ { "name": "Opt-in or Opt-out testing", "type": "BEHAVIORAL" }, { "name": "Focus Group", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "44 Years", "sex": "FEMALE", "summary": "18 Years to 44 Years · Female only" }, "enrollment_count": 41, "start_date": "2012-12", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-01-14", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01994603" }, { "nct_id": "NCT01552369", "title": "CMV Antiviral Prevention Strategies in D+R-Liver Transplants (\"CAPSIL\")", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cytomegalovirus Infection" ], "interventions": [ { "name": "Valganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 205, "start_date": "2012-10-29", "completion_date": "2018-06-22", "has_results": true, "last_update_posted_date": "2021-08-26", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 6, "location_summary": "Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552369" }, { "nct_id": "NCT04980872", "title": "A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)" ], "interventions": [ { "name": "Miransertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "2 Years to 120 Years" }, "enrollment_count": 60, "start_date": "2021-11-02", "completion_date": "2030-02-07", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04980872" }, { "nct_id": "NCT00619645", "title": "Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 8, "start_date": "2007-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619645" }, { "nct_id": "NCT00133445", "title": "Pentavalent DTaP-Hep B-IPV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diphtheria", "Hepatitis B", "Poliomyelitis", "Pertussis", "Tetanus" ], "interventions": [ { "name": "DTaP-Hep B-IPV Vaccine", "type": "BIOLOGICAL" }, { "name": "Monovalent Hep B Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "5 Days", "sex": "ALL", "summary": "Up to 5 Days" }, "enrollment_count": 5, "start_date": "2005-12", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2011-11-07", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 1, "location_summary": "Torrance, California", "locations": [ { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00133445" }, { "nct_id": "NCT00082654", "title": "Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Neuroblastoma", "Ovarian Cancer", "Psychosocial Effects of Cancer and Its Treatment", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "psychosocial assessment and care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": null, "start_date": "2002-03", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082654" }, { "nct_id": "NCT06539169", "title": "FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alpha-Thalassemia", "Beta-Thalassemia", "Amyloidosis", "Amyotrophic Lateral Sclerosis", "Creutzfeld-Jakob Disease", "Cystic Fibrosis", "Duchenne Muscular Dystrophy", "Early-Onset Alzheimer Disease", "Ehlers-Danlos Syndrome", "Huntington Disease", "Gaucher Disease", "GM1 Gangliosidosis", "Myasthenia Gravis", "Pompe Disease", "Sickle Cell Disease", "Transthyretin Amyloid Cardiomyopathy", "Rare Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2024-06-10", "completion_date": "2026-06-10", "has_results": false, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 1, "location_summary": "Los Altos, California", "locations": [ { "city": "Los Altos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06539169" }, { "nct_id": "NCT05491525", "title": "A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neurogenic Detrusor Overactivity" ], "interventions": [ { "name": "Vibegron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Urovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 85, "start_date": "2022-10-12", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-05-22T09:18:39.397Z", "location_count": 6, "location_summary": "Orange, California • Jacksonville, Florida • Wichita, Kansas + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05491525" } ] }